Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF – Get Free Report) saw a significant decline in short interest in April. As of April 30th, there was short interest totaling 78,634 shares, a decline of 51.7% from the April 15th total of 162,794 shares. Currently, 0.4% of the shares of the company are short sold. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.
Newron Pharmaceuticals Price Performance
OTCMKTS:NWPHF opened at $20.00 on Friday. The stock has a 50-day simple moving average of $15.96 and a two-hundred day simple moving average of $11.68. Newron Pharmaceuticals has a 52-week low of $9.10 and a 52-week high of $20.00.
About Newron Pharmaceuticals
Newron Pharmaceuticals SpA is a clinical-stage biopharmaceutical company headquartered in Bresso, Italy, dedicated to developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts focus on small-molecule compounds designed to address unmet medical needs in neurology and psychiatry.
Newron’s lead product, safinamide, is marketed under the brand name Xadago as an adjunctive therapy for patients with mid- to late-stage Parkinson’s disease.
Further Reading
- Five stocks we like better than Newron Pharmaceuticals
- Aeluma’s Post-Earnings Dip Creates a Buying Opportunity
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
